Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Viridian is selling a total of 7,142,858 shares of common stock at a public offering price of $21.00 per share. In addition, Viridian has granted the underwriters a 30-day option to purchase an additional 1,071,428 shares of common stock at the public offering price, less underwriting discounts and commissions.
All of the shares to be sold in the underwritten public offering are being offered by Viridian. The offering is expected to close on or about January 22, 2024, subject to customary closing conditions.
Viridian intends to use the proceeds from the proposed underwritten public offering of its shares of common stock, together with its cash, cash equivalents and short-term investments, to further its clinical development programs, as well as for working capital and general corporate purposes.
Posted In: VRDN